#USA #Tetrous #EnFix #Sherman Oaks #tendon repair

Tetrous, Inc. Expands Clinical Applications of EnFix for Enhanced Tendon Repair Solutions

Tetrous, Inc. Expands Clinical Applications of EnFix

In a significant development for orthopedic surgery, Tetrous, Inc., based in Sherman Oaks, is broadening its innovative EnFix implant applications for treating tendon injuries. This expansion occurs within the context of growing recognition of the enthesis—a critical point of connection between tendon and bone—as a vital biomechanical interface. The company has revealed plans to extend the clinical use of its EnFix implants to various injuries beyond traditional rotator cuff repairs, including:

- Proximal and distal biceps tenodesis
- Insertional Achilles tendinopathy
- Gluteus medius and proximal hamstring reattachment
- Lateral epicondyle repair
- Subscapularis repair during total shoulder arthroplasty

Understanding the Need for Expanded Applications

With high failure rates often seen in bone-to-tendon repairs, the need for innovative solutions has never been more pressing. The expanded applications are estimated to increase the total addressable market for EnFix to an impressive $2 billion in the U.S. alone. The implants, known as EnFix TAC and EnFix RC, are already in clinical use within the United States, Australia, and New Zealand, with plans for broader global accessibility.

The insights shared by several leading surgeons highlight the implant’s versatility. Dr. Peter Howard utilizes EnFix in various procedures, such as biceps tenodesis and gluteal reattachment, appreciating its ease of use and supportive regenerative properties. Likewise, Dr. Gerald Yeo emphasizes EnFix's effectiveness in patients with comorbidities and revision cases, having expanded its use to those suffering from insertional Achilles tendinopathy.

The Biological Advantage of EnFix

The advanced nature of EnFix lies in its composition. These implants are crafted from 100% demineralized bone fiber (DBF), endowed with both osteoinductive and osteoconductive properties essential for fostering natural bone healing. This approach encourages endochondral ossification, essentially recreating how the enthesis developed biologically in embryos.

Preclinical studies have shown promising results, including the formation of Sharpey-like fibers, which significantly enhance biomechanical strength at the tendon-bone interface. Such reinforcements are critical in achieving successful outcomes in biologic enthesis reconstruction.

A Commitment to Ongoing Research

Tetrous, Inc. is actively collecting clinical data across a variety of orthopedic procedures to further validate the effectiveness of its implants. As they gather more evidence, updates and improvements are anticipated, signaling a commitment to innovation in sports medicine and orthopedic surgeries.

The advancements being made with the EnFix technology mark a pivotal step in addressing Enthesis Failure Syndrome, a condition that affects myriad athletes and active individuals. The implants are engineered for seamless integration into existing surgical techniques, offering a biologic augmentation with minimal disruption to the surrounding tissues.

Conclusion

Founded in 2019, Tetrous, Inc. is at the forefront of implementing next-generation treatment options for tendon injuries in sports medicine. The EnFix family of products initially arose from technology developed for spine surgery, which now paves the way for novel applications in addressing soft tissue injuries. With multiple patents issued and an exclusive license for the demineralized bone fiber technology from TheraCell, Tetrous is well-equipped to lead in biologic healing innovations. Their commitment not only signifies strides in medical technology but provides hope for countless patients seeking effective solutions for tendon injuries.

As this company continues to expand its clinical utilization of EnFix implants, the orthopedic community awaits promising results that may redefine recovery standards in tendon repair.